|
WO2021071326A1
|
|
Stable liquid composition, method for preparing same, and formulation comprising same
|
|
WO2020145789A1
|
|
Pharmaceutical composition comprising antibody, device comprising same, and use thereof
|
|
TW202033216A
|
|
Stable liquid composition comprising protein
|
|
WO2020071876A1
|
|
High concentration trastuzumab with reduced viscosity or antigen-binding fragment stabilizing agent thereof
|
|
WO2020060192A1
|
|
Trastuzumab stabilizing liquid formulation containing high concentration of surfactant
|
|
WO2020060179A1
|
|
Trastuzumab antibody stabilizing formulation free of buffering agent
|
|
KR20200029374A
|
|
Liquid Composition Comprising Protein
|
|
TW202023610A
|
|
Pharmaceutical composition comprising anti-tnf alpha antibody
|
|
WO2020138517A1
|
|
PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY
|
|
CN111556744A
|
|
Liquid compositions comprising VEGF antagonists
|
|
WO2018109588A2
|
|
Stable aqueous anti-c5 antibody composition
|
|
KR20180047404A
|
|
Process for reducing undesirable by-product in cell culture
|
|
US2018079796A1
|
|
Anti-tnf-alpha polypeptide composition and use thereof
|
|
KR20160086216A
|
|
Production of a polypeptide by overexpression of malate dehydrogenase
|
|
KR20160086217A
|
|
Enhanced Production of a Recombinant Polypeptide by Overexpression of GLUD
|
|
KR20160085664A
|
|
Enhanced Production of a Recombinant Polypeptide by Overexpression of MPC1
|
|
KR20160085666A
|
|
Production of a Recombinant Polypeptide by Overexpression of GOT1
|
|
KR20160068558A
|
|
Fusion Polynucleotide Containing Murine CMV Promoter and Method of Preparing a Polypeptide of Interest Using the Same
|
|
KR20160051180A
|
|
Production of a Recombinant Polypeptide by Overexpression of fatty acid binding protein
|
|
KR20160051179A
|
|
Production of a polypeptide by PDK inactivation
|
